American Oriental Bioengineering, Inc. 

(Public, NYSE:AOB)   Watch this stock   
Nov 17, 2009
Q3 2009 AMERICAN ORIENTAL BIOENGR INC Earnings Conference Call - Webcast
Nov 16, 2009
Q3 2009 AMERICAN ORIENTAL BIOENGR INC Earnings Release
Sep 15, 2009
AMERICAN ORIENTAL BIOENGR INC at Susquehanna International Group Beijing Management Summit
Sep 14, 2009
AMERICAN ORIENTAL BIOENGR INC at Morgan Stanley Global Healthcare Conference
Sep 11, 2009
AMERICAN ORIENTAL BIOENGR INC at Morgan Stanley Healthcare Corporate Day
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin 18.40% 18.06%
Operating margin 25.67% 24.31%
EBITD margin - 28.06%
Return on average assets 9.87% 10.89%
Return on average equity 16.57% 14.52%
Employees 4,076 -

Address

No. 4018 Jintain Road Anlian Plaza 12F Suit B02 Futian District
Harbin, 518026
China
+86-451-86666601 (Phone)
+86-451-86690967 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Transcripts - SeekingAlpha

American Oriental Bioengineering, Inc. discussions

  View all discussions »

Description

American Oriental Bioengineering, Inc. (AOB) is an integrated, pharmaceutical company engaged in the development, manufacture and commercialization of a range of pharmaceutical and healthcare products. The Company’s business comprises prescription pharmaceutical products, over-the-counter (OTC) pharmaceutical products and nutraceutical products. Its pharmaceutical products have been approved by the Chinese State Food and Drug Administration (SFDA). The Company sells its products primarily to hospitals, clinics, pharmacies and retail outlets at over 100,000 locations in all provinces, including rural areas and cities in China. During the year ended December 31, 2008, AOB marketed over 60 pharmaceutical products in China. On October 18, 2008, the Company acquired Nuo Hua Investment Company Limited. On October 20, 2008, the Company acquired GuangXi HuiKe Pharmaceutical Research and Development Co., Ltd.

Officers and directors

Shujun Liu
Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation - Reuters
Yanchun Li
Chief Financial Officer, Chief Operating Officer, Secretary, Director
Portrait. Age: 40
Bio & Compensation - Reuters
Jun Min
Vice President, Director
Portrait. Age: 49
Bio & Compensation - Reuters
Binsheng Li
Chief Accounting Officer, Director
Portrait. Age: 45
Bio & Compensation - Reuters
Xianmin Wang
Independent Director
Age: 66
Bio & Compensation - Reuters
Cosimo J. Patti
Independent Director
Age: 59
Bio & Compensation - Reuters
Eileen Bridget Brody
Independent Director
Age: 47
Bio & Compensation - Reuters
Lawrence S. Wizel
Independent Director
Age: 66
Bio & Compensation - Reuters
Baiqing Zhang
Independent Director
Age: 56
Bio & Compensation - Reuters